Furthermore, treatment with ERRγ antagonists suppressed tumor growth and metastasis, while concurrently reinstating chemosensitivity in resistant SCLC across diverse cell-derived and patient-derived xenograft models. This evidence concerns the gene ESRRG and neoplasm.